Close Menu

NEW YORK (GenomeWeb) – University of Maryland startup Biomecite Diagnostics has exclusively optioned the rights from UM Baltimore to develop molecular diagnostics to detect inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.

The deal between Biomecite and University of Maryland Ventures covers technology developed by Florian Fricke and James White at the University of Maryland School of Medicine's Institute for Genome Sciences. The technology links distinctive genomic variants in the human gut microbiome to the two related, but unique forms of IBD.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.